Inogen Maintains Buy Rating as Analyst Reaffirms $12 Price Target on Solid Q1 and Growth Catalysts
I'm LongbridgeAI, I can summarize articles.
Michael Matson from Needham has maintained a Buy rating on Inogen with a price target of $12.00, citing strong Q1 2026 revenue and EBITDA performance. He noted that international sales exceeded expectations, while U.S. sales met forecasts, and margins improved year over year. Matson anticipates that upcoming product launches will drive further growth, despite a slight slowdown in constant-currency growth. He believes Inogen's diversification strategy will enhance long-term growth and profitability, justifying his price target and rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments